Skip to main content
Top
Published in: Medical Oncology 1/2011

01-03-2011 | Original paper

Expression of cyclin D2, P53, Rb and ATM cell cycle genes in brain tumors

Authors: Majid Kheirollahi, Masoud Mehr-Azin, Naser Kamalian, Parvin Mehdipour

Published in: Medical Oncology | Issue 1/2011

Login to get access

Abstract

Cyclin D2, P53, Rb and ATM as cell cycle genes regulate cell growth and proliferation. Considering their roles, we assumed that they have different level of mRNA expression in different grades of brain tumors. To determine this point, we investigated the mRNA expression in two types of brain tumors, including astrocytoma and meningioma. The mRNA of 52 brain tumor samples were extracted; cyclin D2, P53, Rb and ATM mRNA expression was quantified using the real-time quantitative reverse-transcription polymerase chain reaction. We compared mRNA expression of these genes between astrocytoma and meningioma tumors and also between different grades of them. Cyclin D2, P53, Rb and ATM had higher expression in astrocytoma than meningioma tumors. Higher grade (III and IV) of astrocytoma tumors had up-regulation for cyclin D2 and ATM genes, but higher grades of these tumors showed down-regulation of P53 and Rb genes. Analysis of relative expression between two grades of meningioma tumors showed a high down-regulation in grade II related to grade I. Also, cyclin D2, P53, Rb and ATM mRNA expression in each group of tumors (meningioma and astrocytoma) showed a highly positive correlation in lower grades. Considering this fact and also different templates of up- and down-regulation for these genes’ interaction in different types of brain tumors, it seems that these genes do not have a unique model of interaction.
Literature
1.
go back to reference Neufeld TP, Edgar BA. Connections between growth and the cell cycle. Curr Opin Cell Biol. 1998;10(6):784–90.PubMedCrossRef Neufeld TP, Edgar BA. Connections between growth and the cell cycle. Curr Opin Cell Biol. 1998;10(6):784–90.PubMedCrossRef
3.
go back to reference Pines J. Cyclins and cyclin-dependent kinases: take your partners. Trends Biochem Sci. 1993;18(6):195–7.PubMedCrossRef Pines J. Cyclins and cyclin-dependent kinases: take your partners. Trends Biochem Sci. 1993;18(6):195–7.PubMedCrossRef
5.
go back to reference Milde-Langosch K, Hagen M, Bamberger A-M, Löning T. Expression and prognostic value of the cell-cycle regulatory proteins, Rb, p16MTS1, p21WAF1, p27KIP1, cyclin E, and cyclin D2, in ovarian cancer. Int J Gynecol Pathol. 2003;122:168–74.CrossRef Milde-Langosch K, Hagen M, Bamberger A-M, Löning T. Expression and prognostic value of the cell-cycle regulatory proteins, Rb, p16MTS1, p21WAF1, p27KIP1, cyclin E, and cyclin D2, in ovarian cancer. Int J Gynecol Pathol. 2003;122:168–74.CrossRef
6.
go back to reference Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13(12):1501–12.PubMedCrossRef Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13(12):1501–12.PubMedCrossRef
7.
go back to reference Ekholm SV, Reed SI. Regulation of G1 cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol. 2000;12:676–84.PubMedCrossRef Ekholm SV, Reed SI. Regulation of G1 cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol. 2000;12:676–84.PubMedCrossRef
8.
go back to reference Evron E, Umbricht CB, Korz D, Raman V, Loeb DM, Niranjan B, et al. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res. 2001;61(6):2782–7.PubMed Evron E, Umbricht CB, Korz D, Raman V, Loeb DM, Niranjan B, et al. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res. 2001;61(6):2782–7.PubMed
9.
go back to reference Dey A, She H, Kim L, Boruch A, Guris DL, Carlberg K, et al. Colony-stimulating factor-1 receptor utilizes multiple signaling pathways to induce cyclin D2 expression. Mol Biol Cell. 2000;11:3835–48.PubMed Dey A, She H, Kim L, Boruch A, Guris DL, Carlberg K, et al. Colony-stimulating factor-1 receptor utilizes multiple signaling pathways to induce cyclin D2 expression. Mol Biol Cell. 2000;11:3835–48.PubMed
10.
go back to reference Lee WH, Hollingsworth RE, Qian YW, Chen PL, Hong F. RB protein as a cellular ‘‘corral’’ for growth-promoting proteins. Cold Spring Harbor Symp Quant Biol. 1991;56:211–7.PubMed Lee WH, Hollingsworth RE, Qian YW, Chen PL, Hong F. RB protein as a cellular ‘‘corral’’ for growth-promoting proteins. Cold Spring Harbor Symp Quant Biol. 1991;56:211–7.PubMed
11.
12.
go back to reference Nevins JR, Leone G, Degregori J, Jakoi L. Role of the Rb/E2F pathway in cell growth control. J Cell Physiol. 1997;173:233–6.PubMedCrossRef Nevins JR, Leone G, Degregori J, Jakoi L. Role of the Rb/E2F pathway in cell growth control. J Cell Physiol. 1997;173:233–6.PubMedCrossRef
15.
go back to reference Pietenpol JA, Vogelstein B. Tumor suppressor genes. No room at the p53 inn. Nature. 1993;365:17–8.PubMedCrossRef Pietenpol JA, Vogelstein B. Tumor suppressor genes. No room at the p53 inn. Nature. 1993;365:17–8.PubMedCrossRef
16.
go back to reference Bardeesy N, Beckwith JB, Pelletier J. Clonal expansion and attenuated apoptosis in Wilms’ tumors are associated with p53 gene mutations. Cancer Res. 1995;55(2):215–9.PubMed Bardeesy N, Beckwith JB, Pelletier J. Clonal expansion and attenuated apoptosis in Wilms’ tumors are associated with p53 gene mutations. Cancer Res. 1995;55(2):215–9.PubMed
17.
go back to reference Ginsberg K, Mechta F, Yaniv M. Wild type p53 can down-modulate the activity of various promotors. Proc Natl Acad Sci USA. 1991;88:9979–83.PubMedCrossRef Ginsberg K, Mechta F, Yaniv M. Wild type p53 can down-modulate the activity of various promotors. Proc Natl Acad Sci USA. 1991;88:9979–83.PubMedCrossRef
18.
go back to reference Mack DH, Vartikar J, Pipas JM. Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature. 1993;363:281–3.PubMedCrossRef Mack DH, Vartikar J, Pipas JM. Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature. 1993;363:281–3.PubMedCrossRef
19.
20.
go back to reference Deb S, Jackson CT, Subler MA. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J Virol. 1992;66:6164–70.PubMed Deb S, Jackson CT, Subler MA. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J Virol. 1992;66:6164–70.PubMed
23.
go back to reference Baross A, Schertzer M, Zuyderduyn SD, Jones SJM, Marra MA, Lansdorp PM. Effect of TERT and ATM on gene expression profiles in human fibroblasts. Genes Chromosomes Cancer. 2004;39:298–310.PubMedCrossRef Baross A, Schertzer M, Zuyderduyn SD, Jones SJM, Marra MA, Lansdorp PM. Effect of TERT and ATM on gene expression profiles in human fibroblasts. Genes Chromosomes Cancer. 2004;39:298–310.PubMedCrossRef
24.
go back to reference Meulmeester E, Pereg Y, Shiloh Y, Jochemsen AG. ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization. Cell Cycle. 2005;4(9):1166–70.PubMedCrossRef Meulmeester E, Pereg Y, Shiloh Y, Jochemsen AG. ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization. Cell Cycle. 2005;4(9):1166–70.PubMedCrossRef
25.
go back to reference Stommel JM, Wahl GM. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J. 2004;23:1547–56.PubMedCrossRef Stommel JM, Wahl GM. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J. 2004;23:1547–56.PubMedCrossRef
26.
go back to reference Pereg Y, Shkedy D, Graaf Pd, Meulmeester E, Edelson-Averbukh M, Salek M, et al. Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage. Proc Natl Acad Sci USA. 2005;102:5056–61.PubMedCrossRef Pereg Y, Shkedy D, Graaf Pd, Meulmeester E, Edelson-Averbukh M, Salek M, et al. Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage. Proc Natl Acad Sci USA. 2005;102:5056–61.PubMedCrossRef
27.
go back to reference Maya R, Balass M, Kim ST, Shkedy D, Leal JF, Shifman O, et al. ATM-dependent phosphorylation of Mdm2 on serine 395: Role in p53 activation by DNA damage. Genes Dev. 2001;15:1067–77.PubMedCrossRef Maya R, Balass M, Kim ST, Shkedy D, Leal JF, Shifman O, et al. ATM-dependent phosphorylation of Mdm2 on serine 395: Role in p53 activation by DNA damage. Genes Dev. 2001;15:1067–77.PubMedCrossRef
28.
go back to reference Lavin MF, Birrell G, Chen P, Kozlov S, Scott S, Gueven N. ATM signaling and genomic stability in response to DNA damage. Mutat Res. 2005;569:123–32.PubMed Lavin MF, Birrell G, Chen P, Kozlov S, Scott S, Gueven N. ATM signaling and genomic stability in response to DNA damage. Mutat Res. 2005;569:123–32.PubMed
29.
go back to reference Szabo CI, Schutte M, Broeks A. Are ATM mutations 7271T->G and IVS10–6T->G really high-risk breast cancer susceptibility alleles? Cancer Res. 2004;64:840–3.PubMedCrossRef Szabo CI, Schutte M, Broeks A. Are ATM mutations 7271T->G and IVS10–6T->G really high-risk breast cancer susceptibility alleles? Cancer Res. 2004;64:840–3.PubMedCrossRef
30.
go back to reference Hall J. The ataxia-telangiectasia mutated gene and breast cancer: gene expression profiles and sequence variants. Cancer Lett. 2005;227(2):105–14.PubMedCrossRef Hall J. The ataxia-telangiectasia mutated gene and breast cancer: gene expression profiles and sequence variants. Cancer Lett. 2005;227(2):105–14.PubMedCrossRef
31.
go back to reference Gutierrez-Enriquez S, Fernet M, Dork T. Functional consequences of ATM sequence variants for chromosomal radiosensitivity. Genes Chromosomes Cancer. 2004;40:109–19.PubMedCrossRef Gutierrez-Enriquez S, Fernet M, Dork T. Functional consequences of ATM sequence variants for chromosomal radiosensitivity. Genes Chromosomes Cancer. 2004;40:109–19.PubMedCrossRef
32.
go back to reference Waha A, Sturne C, Kessler A. Expression of the ATM gene is significantly reduced in sporadic breast carcinomas. Int J Cancer. 1998;78:306–9.PubMedCrossRef Waha A, Sturne C, Kessler A. Expression of the ATM gene is significantly reduced in sporadic breast carcinomas. Int J Cancer. 1998;78:306–9.PubMedCrossRef
33.
go back to reference Kovalev S, Mateen A, Zaika AI, O’Hea BJ, Moll UM. Lack of defective expression of the ATM gene in sporadic breast cancer tissues and cell lines. Int J Oncol. 2000;16:825–31.PubMed Kovalev S, Mateen A, Zaika AI, O’Hea BJ, Moll UM. Lack of defective expression of the ATM gene in sporadic breast cancer tissues and cell lines. Int J Oncol. 2000;16:825–31.PubMed
34.
go back to reference Raptis S, Bapat B. Genetic instability in human tumors. EXS. 2006;96:303–20.PubMed Raptis S, Bapat B. Genetic instability in human tumors. EXS. 2006;96:303–20.PubMed
35.
go back to reference Shiloh Y, Kastan MB. ATM: genome stability, neuronal development, and cancer cross paths. Adv Cancer Res. 2001;83:209–54.PubMedCrossRef Shiloh Y, Kastan MB. ATM: genome stability, neuronal development, and cancer cross paths. Adv Cancer Res. 2001;83:209–54.PubMedCrossRef
38.
go back to reference Tatter SB, Wilson CB, Harsh GRIV. Neuroepithelial tumors of the adult brain. 4th ed. Philadelphia: W.B. Saunders; 1995. Tatter SB, Wilson CB, Harsh GRIV. Neuroepithelial tumors of the adult brain. 4th ed. Philadelphia: W.B. Saunders; 1995.
39.
go back to reference Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol. 1993;3(3):255–68.PubMedCrossRef Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol. 1993;3(3):255–68.PubMedCrossRef
40.
go back to reference Lukas J, Bartkova J, Welcker M, Petersen OW, Peters G, Strauss M, et al. Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types. Oncogene. 1995;10:2125–34.PubMed Lukas J, Bartkova J, Welcker M, Petersen OW, Peters G, Strauss M, et al. Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types. Oncogene. 1995;10:2125–34.PubMed
41.
go back to reference Sweeney KJ, Sarcevic B, Sutherland RL, Musgrove EA. Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells. Oncogene. 1997;14(11):1329–40.PubMedCrossRef Sweeney KJ, Sarcevic B, Sutherland RL, Musgrove EA. Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells. Oncogene. 1997;14(11):1329–40.PubMedCrossRef
42.
go back to reference Sicinski P, Donaher JL, Geng Y, Parker SB, Gardner H, Park MY, et al. Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature (Lond). 1996;384:470–4.CrossRef Sicinski P, Donaher JL, Geng Y, Parker SB, Gardner H, Park MY, et al. Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature (Lond). 1996;384:470–4.CrossRef
43.
go back to reference Yu J, Leung WK, Ng EK, To KF, Ebert MP, Go MY, et al. Effect of Helicobacter pylori eradication on expression of cyclin D2 and p27 in gastric intestinal metaplasia. Aliment Pharmacol Ther. 2001;15(9):1505–11.CrossRef Yu J, Leung WK, Ng EK, To KF, Ebert MP, Go MY, et al. Effect of Helicobacter pylori eradication on expression of cyclin D2 and p27 in gastric intestinal metaplasia. Aliment Pharmacol Ther. 2001;15(9):1505–11.CrossRef
44.
go back to reference Takano Y, Kato Y, Masuda M, Ohshima Y, Okayasu I. Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis. J Pathol. 1999;189:194–200.PubMedCrossRef Takano Y, Kato Y, Masuda M, Ohshima Y, Okayasu I. Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis. J Pathol. 1999;189:194–200.PubMedCrossRef
45.
go back to reference Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene. 1993;8:2127–33.PubMed Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene. 1993;8:2127–33.PubMed
46.
go back to reference Tam SW, Theodoras AM, Shay JW, Draetta GF, Pagano M. Differential expression and regulation of cyclin D1 protein in normal and tumor human cells: association with Cdk4 is required for cyclin D1 function in G1 progression. Oncogene. 1994;9:2663–74.PubMed Tam SW, Theodoras AM, Shay JW, Draetta GF, Pagano M. Differential expression and regulation of cyclin D1 protein in normal and tumor human cells: association with Cdk4 is required for cyclin D1 function in G1 progression. Oncogene. 1994;9:2663–74.PubMed
47.
go back to reference Schmidt BA, Rose A, Steinhoff C, Strohmeyer T, Hartmann M, Ackermann R. Up-regulation of cyclin-dependent kinase 4/cyclin D2 expression but down-regulation of cyclin-dependent kinase 2/cyclin E in testicular germ cell tumors. Cancer Res. 2001;61:4214–21.PubMed Schmidt BA, Rose A, Steinhoff C, Strohmeyer T, Hartmann M, Ackermann R. Up-regulation of cyclin-dependent kinase 4/cyclin D2 expression but down-regulation of cyclin-dependent kinase 2/cyclin E in testicular germ cell tumors. Cancer Res. 2001;61:4214–21.PubMed
48.
go back to reference Diccianni MB, Omura-Minamiawa M, Batova A, Le T, Bridgeman L, Yu AL. Frequent deregulation of p16 and the p16/G1 cell cycle-regulatory pathway in neurobalastoma. Int J Cancer. 1999;80:145–54.PubMedCrossRef Diccianni MB, Omura-Minamiawa M, Batova A, Le T, Bridgeman L, Yu AL. Frequent deregulation of p16 and the p16/G1 cell cycle-regulatory pathway in neurobalastoma. Int J Cancer. 1999;80:145–54.PubMedCrossRef
49.
go back to reference Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. 1995;55:6161–5.PubMed Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. 1995;55:6161–5.PubMed
50.
51.
go back to reference Quinlan DC, Davidson AS, Summers CL. Accumulation of p53 correlates with a poor prognosis in human lung cancers. Cancer Res. 1992;53:4828–31. Quinlan DC, Davidson AS, Summers CL. Accumulation of p53 correlates with a poor prognosis in human lung cancers. Cancer Res. 1992;53:4828–31.
52.
go back to reference Fontanini G, Boldrini S, Vignati S. Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung cancer. Eur J Cancer. 1998;34:718–23.PubMedCrossRef Fontanini G, Boldrini S, Vignati S. Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung cancer. Eur J Cancer. 1998;34:718–23.PubMedCrossRef
53.
go back to reference Maeda T, Matsumura S, Hiranuma H. Expression of vascular endothelial growth factor in human oral squamous cell carcinoma: its association with tumour progression and p53 gene status. J Clin Pathol. 1998;51:771–5.PubMedCrossRef Maeda T, Matsumura S, Hiranuma H. Expression of vascular endothelial growth factor in human oral squamous cell carcinoma: its association with tumour progression and p53 gene status. J Clin Pathol. 1998;51:771–5.PubMedCrossRef
54.
go back to reference Ambs S, Bennett WP, Merriam WG. Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. Br J Cancer. 1998;78(2):233–9.PubMedCrossRef Ambs S, Bennett WP, Merriam WG. Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. Br J Cancer. 1998;78(2):233–9.PubMedCrossRef
55.
go back to reference Ye S, Zhong X, Chen Y. p53 and vascular endothelial growth factor expression in astrocytoma and their relation to angiogenesis. Zhonghua Zhong Liu Za Zhi. 2001;23(4):326–9.PubMed Ye S, Zhong X, Chen Y. p53 and vascular endothelial growth factor expression in astrocytoma and their relation to angiogenesis. Zhonghua Zhong Liu Za Zhi. 2001;23(4):326–9.PubMed
56.
go back to reference Danks RA, Chopra G, Gonzales MF, Orian JM, Kaye AH. Aberrant p53 expression does not correlate with the prognosis in anaplastic astrocytoma. Neurosurgery. 1995;37(2):246–54.PubMedCrossRef Danks RA, Chopra G, Gonzales MF, Orian JM, Kaye AH. Aberrant p53 expression does not correlate with the prognosis in anaplastic astrocytoma. Neurosurgery. 1995;37(2):246–54.PubMedCrossRef
57.
go back to reference Malmer BS, Feychting M, Lönn S, Lindström S, nberg HG, Ahlbom A, et al. Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma. J Neurooncol. 2007;82:229–37.PubMedCrossRef Malmer BS, Feychting M, Lönn S, Lindström S, nberg HG, Ahlbom A, et al. Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma. J Neurooncol. 2007;82:229–37.PubMedCrossRef
58.
go back to reference Mehdipour P, Habibi L, Mohammadi-Asl J, Kamalian N, Azin MM. Three-hit hypothesis in astrocytoma: tracing the polymorphism D1853N in ATM gene through a pedigree of the proband affected with primary brain tumor. J Cancer Res Clin Oncol. 2008;134:1173–80.PubMedCrossRef Mehdipour P, Habibi L, Mohammadi-Asl J, Kamalian N, Azin MM. Three-hit hypothesis in astrocytoma: tracing the polymorphism D1853N in ATM gene through a pedigree of the proband affected with primary brain tumor. J Cancer Res Clin Oncol. 2008;134:1173–80.PubMedCrossRef
Metadata
Title
Expression of cyclin D2, P53, Rb and ATM cell cycle genes in brain tumors
Authors
Majid Kheirollahi
Masoud Mehr-Azin
Naser Kamalian
Parvin Mehdipour
Publication date
01-03-2011
Publisher
Springer US
Published in
Medical Oncology / Issue 1/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-009-9412-8

Other articles of this Issue 1/2011

Medical Oncology 1/2011 Go to the issue